Surgical robotics specialist Virtual Incision Corp. has raised $18 million in its series B round. The round was co-led by new investor Sinopharm Capital, the private equity fund initiated by China's Sinopharm Group, and existing investor Bluestem Capital, with participation from Prairiegold Venture Partners and others.

Intersect Ent Inc. has received approval from the FDA for its Sinuva sinus implant, a targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery. Upon news of the approval, shares of the Menlo Park, Calif.-based company (NASDAQ:XENT) jumped 15 percent, closing at $32.75. The implant is being regulated as a drug, marking Intersect's first full-fledge foray into the pharma industry.

Stryker Corp. is poised to acquire Entellus Medical Inc. in a deal for $24 per share, valued at about $662 million. Plymouth, Minn.-based Entellus designs minimally invasive products in the ear, nose and throat (ENT) market and brought in $23 million in 3Q17. News of the impending merger drove Entellus (NASDAQ:ENTL) shares up above 50 percent during trade on Thursday. Entellus shares closed at $23.99. The firm's board unanimously signed off on the transaction.

Smith & Nephew plc. is ending 2017 by closing its acquisition of Rotation Medical Inc. for $125 million in cash, plus an additional $85 million in potential milestone payments. The London-based company first revealed it would pick up the bioinductive implant-maker back in October in a deal that would be neutral for earnings in 2018 and boost them in 2019. (See BioWorld MedTech, Oct. 24, 2017.)